Archives: Agenda

• How do we look at data transparency issues when scaling AI?
• Case study on AI rights and a look at recently released survey discussing where things need to change
• Without GDPR, what can be done to protect patients regarding data sovereignty?
• Delving into the unique and amplified challenges for AI risk assessment
• How we can effectively leverage AI in our heavily regulated environment?

• Understand key elements of the FDA’s recent directives and their implications for increasing representation in clinical trials
• Review data on the growing emphasis on diversity in sponsor submissions and filings, and learn how to align strategies with industry trends
• Discover practical methods to recruit, engage, and retain underrepresented populations in clinical research
• Examine how prioritizing diversity improves study validity, compliance, and applicability, supported by real-world data

• Gain insights into the complete process of end-to-end financial management.
• Identify the inefficiencies caused by manual steps and siloed technologies.
• Explore how combining services and software can optimize the financial management process.
• Learn how IQVIA Technologies’ expertise and global reach can support your financial management needs, whether insourced or outsourced.

• The evolving landscape of clinical trials and the need for more engaged sites: trial complexity, competition, and site staff turnover
• How the CRO fits into addressing site support as a focal point
• The sponsor’s role in site support
• The road forward: methods of addressing site support

• Are we playing technology catch-up: What can we learn and adapt from other industries, and how can we implement this on scale despite increased regulation?
• Lots of clinical management systems are generic but do we have ones that are clinically focused: Are you reaching the right audience in the right way and how can CROs get recognized by biotechs?
• Recognizing the impact of technology solutions on the patients journey and ways to progress this even further
• How do smaller biotechs prepare their supply chains for IRT adoption and compliance?

Chair: Joshua Cox, Vice President of Clinical Data & Analytics Capabilities, Eli Lilly and Company

• Discuss why financial accruals for clinical and R&D activities are still so challenging after all these years
• Using real-life case studies, discuss common pain-points experienced by biopharma companies when it comes to financial accruals
• Ponder easy implementations you can consider for your accruals processes that can significantly improve efficiency and decrease pain

• Breaking through the complexity of phase 1 studies
• Prioritizing Phase 1 schedule
• Optimizing efficiencies for NDA-Enabling studies